Suvaxyn PRRS MLV
سوفاكسين بي آر آر إس لقاح متلازمة الخنازير التنفسية والتناسلية الحي المضعف
Suvaxyn PRRS MLV is a modified live vaccine containing attenuated Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain 96V198 (European genotype, Type 1). Indicated for active immunization of clinically healthy pigs from 1 day of age to reduce viraemia, respiratory clinical signs, and viral shedding caused by PRRS virus.
Dosage Form
Injection
Product Type
Biological
Manufacturer
Package
Vials of 10, 50, and 100 doses lyophilisate with sterile solvent
Dosages
| Species | Dosage | Route | Duration |
|---|---|---|---|
| Swine | Reconstitute lyophilisate with solvent and administer 2 mL intramuscularly in the neck musculature | Intramuscular (IM) | Single dose from 1 day of age; breeding gilts/sows vaccinated prior to mating |
Withdrawal Periods
| Species | Meat (days) | Milk (days) | Eggs (days) |
|---|---|---|---|
| Swine | 0 |
Indications
-
Active immunization of clinically healthy pigs from 1 day of age to reduce viraemia and nasal shedding caused by infection with European (Type 1) strains of PRRS virus.
-
Reduction of lung lesions and clinical respiratory disease associated with PRRS in fattening pigs.
Contraindications
-
Do not use in PRRS-negative herds where the presence of PRRS virus has not been established.
-
Do not vaccinate clinically diseased pigs.
Precautions
-
Vaccine virus may spread to in-contact pigs for several weeks following vaccination; adhere to biosecurity protocols.
Side Effects
-
Transient rise in rectal temperature (up to 1.5°C) within 24 hours of vaccination, resolving spontaneously.
Images
Documents
-
Download
Suvaxyn PRRS MLV Prescribing Information
Leaflet
Active Ingredients
Diseases
No diseases linked.
Related Products
No data available
Information has not been added yet.
Related Products By Active Ingredient
No data available
Information has not been added yet.
Companies
-
Zoetis
Manufacturer
Alternatives
No alternatives available.